Evidence map›Paper›PMID 42583077›Full record

ReviewFrontiers in immunology2026

Practical considerations for monitoring patients with familial Mediterranean fever: review of evidence and expert opinion.

Jasmin B Kuemmerle-Deschner, Abdurrahman Tufan, Luca Cantarini, Andreas Clemens, Albert Schuen, Ruby Haviv

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jasmin B Kuemmerle-Deschnerautoinflammation reference center Tübingen (arcT), Division of Paediatric Rheumatology, Department of Paediatrics, University Hospital Tübingen, Tübingen, Germany.
Abdurrahman TufanDivision of Rheumatology, Department of Internal Medicine, Gazi University Faculty of Medicine, Ankara, Türkiye.
Luca CantariniDepartment of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy.
Andreas ClemensNovartis Pharma AG, Basel, Switzerland.
Albert SchuenNovartis Pharma AG, Basel, Switzerland.
Ruby HavivDepartment of Pediatrics, Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, and School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Effective monitoring is critical in familial Mediterranean fever (FMF), to guide a treat-to-target approach to management and to prevent long-term complications. Here we review current evidence and guidance on monitoring patients with FMF in clinical practice, and propose flexible recommendations for long-term monitoring in FMF, that can be tailored to the needs and setting of the individual clinic. Methods: In this expert-informed narrative review based on a systematic literature search, published evidence was used to inform and augment the clinical experience and expert opinion of a group of international experts in FMF. Results: A total of 42 publications were included for review, including several treatment guidelines for FMF as well as publications relating to clinical biomarkers (primarily acute phase reactants), patient-reported outcomes and various disease scales and scores. While much of the guidance from these publications is broadly consistent, with agreement on core monitoring principles and parameters, the lack of validated, evidence-based recommendations highlights the need for flexibility in clinical practice. Conclusion: This review provides a comprehensive schedule of parameters with suggested monitoring frequencies, centred around three key principles of FMF monitoring: assessing disease characteristics, monitoring for subclinical inflammation, and assessing the tolerability of current medication and possible side effects. It is our hope that this will prove a useful starting point for creation of tailored monitoring schedules by clinics based on their specific resources, patient needs, and clinical priorities.

Indexed as

Familial Mediterranean FeverBiomarkersDisease ManagementHumansBiomarkersbiomarkersdisease activityfamilial Mediterranean fevermanagementpatient monitoringtreat-to-target

Identifiers

PMID42583077
PMCPMC13459442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.